EpiThany, Merck KGaA, Pfizer to evaluate combination of avelumab and EP-101 STEMVAC in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

EpiThany today announced that they have entered into a collaboration agreement with Merck KGaA, Darmstadt, Germany, and Pfizer to evaluate avelumab*, a human anti-PD-L1 antibody, and EP-101 STEMVAC, a multi-antigen, polyepitope vaccine, in a phase II trial in women with breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

In recent months, several directors of cancer centers, appearing on The Directors, a segment of The Cancer Letter Podcast, mentioned that their institutions are increasingly providing small grants—typically in the range of $50,000—to scientists to enable them to keep their labs open.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login